{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464378599
| IUPAC_name = (17β)-3-(cyclopentyloxy)-17-ethynylestra-1,3,5(10)-trien-17-ol
| image = Quinestrol.png
| width = 250

<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|CONS|quinestrol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| IUPHAR_ligand = 7097
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 152-43-2
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 9046
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04575
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8694
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JR0N7XD5GZ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00576
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8716
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201165

<!--Chemical data-->
| C = 25 | H = 32 | O = 2
| molecular_weight = 364.52 g/mol
| smiles = O(c1ccc2c(c1)CC[C@H]3[C@@H]4CC[C@](C#C)(O)[C@@]4(C)CC[C@H]23)C5CCCC5
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PWZUUYSISTUNDW-VAFBSOEGSA-N
| synonyms = W-3566;<br /><small>3-Cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-''6H''-cyclopenta[''a'']phenanthren-17-ol</small>
}}

'''Quinestrol''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) (brand names '''Agalacto-Quilea''', '''Basaquines''', '''Eston''', '''Estrovis''', '''Estrovister''', '''Plestrovis''', '''Qui-Lea'''), also known as '''ethinylestradiol 3-cyclopentyl ether''' ('''EE2CPE'''), is a [[Organic compound#Synthetic compounds|synthetic]], [[steroid]]al [[estrogen]] used in [[Hormone replacement therapy (menopause)|hormone replacement therapy]] and occasionally to treat [[breast cancer]] and [[prostate cancer]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA522|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=522–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA243|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=243–}}</ref><ref name="Zink1988">{{cite book|author=Christoph Zink|title=Dictionary of Obstetrics and Gynecology|url=https://books.google.com/books?id=EQlvzV9V7xIC&pg=PA204|date=1 January 1988|publisher=Walter de Gruyter|isbn=978-3-11-085727-6|pages=204–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA905|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=905–}}</ref> It is a [[prodrug]] of [[ethinylestradiol]] (with [[cyclopentanol]] also being formed) with no intrinsic estrogenic activity of its own, and has a very long [[terminal half-life]] of more than 120 hours due to enhanced [[lipophilicity]].<ref name="OettelSchillinger2012">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA248|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|pages=248–}}</ref> Because of its much longer terminal half-life, quinestrol is two to three times as potent as ethinylestradiol.<ref name="Meikle1999">{{cite book|author=A. Wayne Meikle|title=Hormone Replacement Therapy|url=https://books.google.com/books?id=ja2nBgAAQBAJ&pg=PA381|date=1 June 1999|publisher=Springer Science & Business Media|isbn=978-1-59259-700-0|pages=381–}}</ref> The drug was marketed as '''Estrovis''' in the [[United States]] by [[Parke Davis]] and as '''Qui-Lea''' in [[Argentina]],<ref name="IndexNominum2000" /> but is reportedly not currently marketed.<ref name="Meikle1999" /> However, it does appear to be available as an [[oral contraceptive]] in combination with [[progestin]]s in Argentina and [[China]].<ref name="Drugs.com">https://www.drugs.com/international/quinestrol.html</ref> Quinestrol was described in the literature in 1967.<ref name="Elks2014" />

==See also==
* [[Ethinylestradiol sulfonate]]
* [[Estradiol cypionate]]
* [[Mestranol]]
* [[Moxestrol]]
* [[Nilestriol]]
* [[Quinestradol]]
* [[Quingestanol]]
* [[Quingestanol acetate]]

==References==
{{Reflist|2}}


{{Estrogens and antiestrogens}}
{{Estrogen receptor modulators}}

[[Category:Antigonadotropins]]
[[Category:Estranes]]
[[Category:Synthetic estrogens]]
[[Category:Cyclopentanes]]


{{genito-urinary-drug-stub}}